Evidence
The source index
Every external source this index cites — studies, trial registries, regulatory documents and references — collected, de-duplicated and rated. The rating rates the source, not the strength of the evidence: an animal study in a peer-reviewed journal is independent because the record is sound; whether it supports a human claim is a separate question, answered by each compound's evidence tier.
522
Cited sources
100%
Independent
512
Papers
9
Trials & regulators
Independent 521
Published or checked by a third party with no stake in the answer — peer review, a public trial registry, an approved label, or a regulator.
Interested 1
A named, accountable publisher that either has a stake in the answer or is retelling someone else’s record. Worth reading, worth checking against a primary source.
Every source
522 cited, most-referenced first
- paperTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions12×
- paperPreclinical rodent work on BPC-157 and tendon healing8×
- labelFDA bulk drug substances nominated for compounding — 503A and 503B lists4×
- paperSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance4×
- labelFDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list3×
- paperInjectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians3×
- regulatorWADA Prohibited List — growth factors and peptide hormones (class S2)3×
- labelFDA drug shortage database — GLP-1 receptor agonist products2×
- regulatorEMA medicine approvals — GLP-1 and dual-agonist products2×
- labelFDA declares the semaglutide shortage resolved, winding down compounding2×
- labelFDA warning letter to SwissChems over semaglutide and retatrutide2×
- paperEmerging pharmacotherapies for obesity: A systematic review2×
- paperTirzepatide as Compared with Semaglutide for the Treatment of Obesity2×
- paperNovel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function2×
- paperIn Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential2×
- paperAn orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity2×
- paperPeptides and Ageing2×
- paperStudies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology2×
- paperFunctional Connectomic Approach to Studying Selank and Semax Effects2×
- paperIpamorelin, the first selective growth hormone secretagogue2×
- paperThe mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance2×
- paperBeyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males2×
- labelFDA warning letter database — research chemical and peptide sellers1×
- labelFDA warns peptide vendors selling retatrutide as a 'research' GLP-11×
- refMHRA position on unlicensed medicines sold direct to the public1×
- paperManaging fatigue in sarcoidosis - A systematic review of the evidence1×
- paperThe time to develop treatments for diabetic neuropathy1×
- paperSafety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study1×
- paperCibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain1×
- paperComparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network met1×
- paperCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity1×
- paperCagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes1×
- paperOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-con1×
- paperProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy ad1×
- paperPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog1×
- paperCognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies1×
- paperDSIP in insomnia1×
- paperEffects of DSIP on narcolepsy1×
- paperA clinical trial with DSIP1×
- paperEffects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia1×
- paperPineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa1×
- paperEffects of topical copper tripeptide complex on CO2 laser-resurfaced skin1×
- paperA prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers1×
- paperEvaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits1×
- paperSupplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, 1×
- paperEffectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials1×
- paperEffect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review1×
- paperRandomized controlled trial of oral glutathione supplementation on body stores of glutathione1×
- paperDifferential effects of insulin-like growth factor-I and gonadotropins on the proliferative activity of two subgroups of granulosa cells: cumulus oophorus and m1×
- paperProspective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patie1×
- paperPharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers1×
- paperKisspeptin as a predictor of miscarriage: a systematic review1×
- paperElinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women1×
- paperSerum kisspeptin levels in polycystic ovary syndrome: A meta-analysis1×
- paperKisspeptin and its Current Clinical Status-A Systematic Review1×
- paperAfamelanotide for Erythropoietic Protoporphyria1×
- paperLong-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria1×
- paperAfamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial1×
- paperA systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo1×
- paperMelanotan-induced priapism: a hard-earned tan1×
- paperMelanotan-associated melanoma1×
- paperMelanotan II: a possible cause of renal infarction: review of the literature and case report1×
- paperA glimpse into the underground market of melanotan1×
- paperEffects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activat1×
- paperCirculating levels of MOTS-c in patients with breast cancer treated with metformin1×
- paperRepeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization1×
- paperImpact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer1×
- paperThe efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-c1×
- paperEvaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review1×
- paperNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women1×
- paperZinc promotes microbial p-coumaric acid production that protects against cholestatic liver injury1×
- paperSafety Profile of Bremelanotide Across the Clinical Development Program1×
- paperBremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder1×
- paperRe-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women1×
- paperFemale Sexual Dysfunction and the Placebo Effect: A Meta-analysis1×
- paperTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial1×
- paperEfficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Tr1×
- paperSeven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and networ1×
- paper[Optimization of the treatment of anxiety disorders with selank]1×
- paper[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]1×
- paper[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]1×
- paperPredictive factors of the presence of pulmonary embolism in patients with interstitial lung disease: Observational study1×
- paperOnce-Weekly Semaglutide in Adults with Overweight or Obesity1×
- paperWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension1×
- paperEffect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical T1×
- paper[The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]1×
- paper[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]1×
- paper[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]1×
- paper[Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]1×
- paperQuantitative growth hormone secretion and final adult height1×
- paperAnterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report1×
- paperGrowth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone1×
- paperGrowth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous beta-thalassemia1×
- paperEfficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study1×
- paperMalignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis1×
- paperThymosins: structure, function and therapeutic applications1×
- paperA randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers1×
- paperThe effect of thymosin treatment of venous ulcers1×
- paperEfficacy and safety of tesamorelin in people with HIV on integrase inhibitors1×
- paperBody composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized co1×
- paperApproach to the Patient With Lipodystrophy1×
- paperEffects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity1×
- paperThe efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial1×
- paperNeoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial1×
- paperComprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials1×
- paperEfficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials1×
- paperTirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity1×
- paperTirzepatide Once Weekly for the Treatment of Obesity1×
- paperTirzepatide for Obesity Treatment and Diabetes Prevention1×
- paperIntravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled t1×
- paperBrief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestina1×
- paperThe Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial1×
- paperErectile dysfunction: a global review of intracavernosal injectables1×
- paperEffect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial1×
- paperClinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis1×
- paperAbaloparatide1×
- paperAbaloparatide: A new pharmacological option for osteoporosis1×
- paperAbaloparatide: A review of preclinical and clinical studies1×
- paperThe effect of tripeptide-copper complex on human hair growth in vitro1×
- paperTryptophan and Cysteine Oxidation Products Dominate in α-Lactalbumin-Derived Peptides Analyzed with LC-MS(n)1×
- paperX-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties1×
- paperHuman serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death1×
- paperCopper stimulates the synthesis and release of interleukin-8 in human endothelial cells: a possible early role in systemic inflammatory responses1×
- paperCopper inhibits activated protein C: protective effect of human albumin and an analogue of its high-affinity copper-binding site, d-DAHK1×
- paperNTRK1 knockdown induces mouse cognitive impairment and hippocampal neuronal damage through mitophagy suppression via inactivating the AMPK/ULK1/FUNDC1 pathway1×
- paperAMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching1×
- paperThe AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury1×
- paperNicotinohydrazide1×
- paper6-Chloro-3-[5-(4-fluoro-phen-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-2-methyl-4-phenyl-quinoline1×
- paperO304 is a mitochondrial uncoupler which extends C. elegans lifespan and induces vasorelaxation of rat mesenteric arteries1×
- paperMitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control1×
- paperBAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils1×
- paperBeneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease1×
- paperDiverse actions of 15 structurally unrelated mitochondrial uncouplers in cells and mice1×
- paperTargeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice1×
- paperRestricting bioenergetic efficiency enhances longevity and mitochondrial redox capacity in Drosophila melanogaster1×
- paperCerebrolysin for acute ischaemic stroke1×
- paperCerebrolysin for vascular dementia1×
- paperCerebrolysin for acute ischaemic stroke1×
- paperCerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis1×
- paperCerebrolysin for acute ischaemic stroke1×
- paperCerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis1×
- paperEloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept1×
- paperEloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled tri1×
- paperEloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept1×
- paperAmylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials1×
- paperLong-acting amylin-related peptides as therapies for obesity and type 2 diabetes1×
- paperBeyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs1×
- paperFollistatin1×
- paperFollistatin drives neuropathic pain in mice through IGF1R signaling in nociceptive neurons1×
- paperFructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance1×
- paperFollistatin and follistatin-like 3 in metabolic disorders1×
- paperHeparin-mediated dimerization of follistatin1×
- paperActivin/follistatin and atherosclerosis--a review1×
- paperHuman Chorionic Gonadotropin1×
- paperPhysiology, Chorionic Gonadotropin1×
- paperHuman Chorionic Gonadotropin and Breast Cancer1×
- paperEquine chorionic gonadotropin1×
- paperHuman chorionic gonadotropin-secreting osteosarcoma1×
- paperHuman chorionic gonadotropin tests1×
- paperEfficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study1×
- paperSomatrem1×
- paperSomatropin1×
- paperSomatrogon1×
- paperSafety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort1×
- paperLonapegsomatropin1×
- paperA new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review1×
- paperHuman Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells1×
- paperHyperglycemic action of synthetic C-terminal fragments of human growth hormone1×
- paperThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration1×
- paperl-Carnitine Supplementation in Recovery after Exercise1×
- paperL-carnitine--metabolic functions and meaning in humans life1×
- paperLevocarnitine1×
- paperPropionyl-L-carnitine1×
- paperL-carnitine: to fuel or not to fuel the failing heart?1×
- paperPharmacokinetics of L-carnitine1×
- paperLarazotide acetate: a pharmacological peptide approach to tight junction regulation1×
- paperLarazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials1×
- paperAntibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment1×
- paperViral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide1×
- paperTargeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection1×
- paperThe Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases1×
- paperOnce-Weekly Mazdutide in Chinese Adults with Obesity or Overweight1×
- paperSafety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, 1×
- paperA phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity1×
- paperMazdutide: First Approval1×
- paperBeyond weight loss: multisystem benefits of obesity medications1×
- paperMelanotan-II reverses memory impairment induced by a short-term HF diet1×
- paperMelanotan II User Experience: A Qualitative Study of Online Discussion Forums1×
- paperCLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists1×
- paperMelanotan-II reverses autistic features in a maternal immune activation mouse model of autism1×
- paperDiscovery and development of novel melanogenic drugs. Melanotan-I and -II1×
- paperMelanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food1×
- paperMelanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice1×
- paperMecasermin for primary insulin-like growth factor-1 deficiency1×
- paperMecasermin1×
- paperMecasermin rinfabate1×
- paperMecasermin (recombinant human insulin-like growth factor I)1×
- paperTreatment with Recombinant Human Insulin-Like Growth Factor-1 in Severe Primary IGF Deficiency and Beyond1×
- paperRetrospective analysis: The application of human menopausal gonadotropin combined with letrozole for IUI in patients undergoing artificial insemination by husba1×
- paperHuman menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a ran1×
- paperPulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 c1×
- paperHighly Purified Human Menopausal Gonadotropin (Menopur(®)): A Profile of Its Use in Infertility1×
- paperSubcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles1×
- paperImplantation, abortion, and birth after in vitro fertilization using the natural menstrual cycle or follicular stimulation with clomiphene citrate and human men1×
- paperUnderstanding and overcoming metformin gastrointestinal intolerance1×
- paperClinical pharmacokinetics of metformin1×
- paperMetformin: from mechanisms of action to therapies1×
- paperMetformin and the gastrointestinal tract1×
- paperMetformin: historical overview1×
- paperClinical pharmacokinetics of metformin1×
- paperThe Potentials of Methylene Blue as an Anti-Aging Drug1×
- paperAdministration of methylene blue in septic shock: pros and cons1×
- paperMethylene blue1×
- paperMethylene Blue1×
- paperMethylene Blue1×
- paperMethylene-blue-associated encephalopathy1×
- paperDaily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity1×
- paperOrforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and m1×
- paperOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes1×
- paperOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment1×
- paperOrforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, 1×
- paperDisposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants1×
- paperIs Oxytocin "Nature's Medicine"?1×
- paperOxytocin1×
- paperOxytocin1×
- paperOxytocin redux1×
- paperOxytocin and Olfaction1×
- paperOxytocin1×
- paperShortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity1×
- paperPinealon increases cell viability by suppression of free radical levels and activating proliferative processes1×
- paperPinealon protects the rat offspring from prenatal hyperhomocysteinemia1×
- paper[Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]1×
- paper[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]1×
- paper[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]1×
- paperSirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial1×
- paperRapamycin (sirolimus, rapamune)1×
- paperSirolimus1×
- paperSirolimus1×
- paperSirolimus1×
- paperRapamycin (sirolimus): a two-edged sword?1×
- paperRetatrutide-A Game Changer in Obesity Pharmacotherapy1×
- paperRetatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials1×
- paperThe power of three: Retatrutide's role in modern obesity and diabetes therapy1×
- paperRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-gr1×
- paperTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial1×
- paperEfficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and e1×
- paperEffects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised1×
- paperA Synthetic ERR Agonist Alleviates Metabolic Syndrome1×
- paperChemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling1×
- paperSynthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity1×
- paperDevelopment and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-9151×
- paperNuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators1×
- paper[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]1×
- paperTesofensine, a monoamine reuptake inhibitor for the treatment of obesity1×
- paperTesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons1×
- paperWeight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease1×
- paperTesofensine and weight loss1×
- paperTesofensine and weight loss1×
- paperTesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor p1×
- paperThymalin: Activation of Differentiation of Human Hematopoietic Stem Cells1×
- paper[Geroprotective effect of thymalin and epithalamin]1×
- paperThe Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-191×
- paper[Influence of peptides from pineal gland on thymus function at aging]1×
- paperChornobyl catastrophe: cytogenetic effects of low dose ionizing radiation and their modification1×
- paperTriptorelin1×
- paperTriptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis1×
- paperTriptorelin for the treatment of endometriosis1×
- paperTriptorelin embonate (6-month formulation)1×
- paperTriptorelin depot for the treatment of children 2 years and older with central precocious puberty1×
- paperTriptorelin associated adverse events evaluated using FAERS pharmacovigilance data1×
- paper[Investigation of antihypoxic properties of short peptides]1×
- paperBioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people1×
- paper[Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]1×
- paperAnti-aging peptide bioregulators induce reactivation of chromatin1×
- paperMultifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review1×
- paperGastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing1×
- paperIntra-Articular Injection of BPC 157 for Multiple Types of Knee Pain1×
- paperStable Gastric Pentadecapeptide BPC 157 and Wound Healing1×
- paperEmerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review1×
- paperBPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing1×
- paperRegeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing1×
- paperPentadecapeptide BPC 157 and the central nervous system1×
- paperDelta sleep-inducing peptide1×
- paperDelta-sleep-inducing peptide (DSIP): a review1×
- paperDelta sleep-inducing peptide (DSIP): a still unresolved riddle1×
- paperDelta-sleep-inducing peptide (DSIP): an update1×
- paperDelta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity?1×
- paperDelta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke1×
- paper[Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide]1×
- paperRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data1×
- paperThe potential of GHK as an anti-aging peptide1×
- paperGlycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway1×
- paperGHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration1×
- paperTopically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective1×
- paperThe glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 61×
- paperClinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities1×
- paperRecombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris1×
- paperIGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep1×
- paperAttenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets1×
- paperRevolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regener1×
- paperIntranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male1×
- paperSheep recombinant IGF-1 promotes organ-specific growth in fetal sheep1×
- paperAction of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers1×
- paperCoronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep1×
- paperThymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids1×
- paperbeta-Thymosins1×
- paperThymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications1×
- paperIdentification of glutamine as a potential therapeutic target in dry eye disease1×
- paperCardioprotection by Thymosin Beta 41×
- paperThe beta-thymosin enigma1×
- paperThymosin beta 4 interactions1×
- paperThymosin beta 41×
- paperVitiligo: Pathogenesis and New and Emerging Treatments1×
- paperFrom pathogenesis of acne vulgaris to anti-acne agents1×
- paperVitiligo, from Pathogenesis to Therapeutic Advances: State of the Art1×
- paperAfamelanotide1×
- paperTreatment Advances in Vitiligo: An Updated Review1×
- paperX-Linked Protoporphyria1×
- paperPhototherapy for Vitiligo1×
- paperAfamelanotide in protoporphyria and other skin diseases: a review1×
- paperPT-141 Palatin1×
- paperHypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment1×
- paperBremelanotide1×
- paperBremelanotide1×
- paperBremelanotide: First Approval1×
- paperAn effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist1×
- paperTargeting the central melanocortin system for the treatment of metabolic disorders1×
- paperSafety of Semaglutide1×
- paperSemaglutide for the treatment of obesity1×
- paperSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled,1×
- paperEfficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis1×
- paperSemaglutide lowers body weight in rodents via distributed neural pathways1×
- paperWegovy (semaglutide): a new weight loss drug for chronic weight management1×
- paperClinical Pharmacokinetics of Semaglutide: A Systematic Review1×
- paperRisk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide1×
- paperSemax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice1×
- paperSemax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats1×
- paperSemax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models1×
- paperSemax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing1×
- paperSemax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia1×
- paperSemax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents1×
- paperThymosin alpha-11×
- paperAging and Thymosin Alpha-11×
- paperThymosin alpha-1 treatment in chronic hepatitis B1×
- paperA Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection1×
- paperClinical applications of thymosin alpha-11×
- paperThymosin alpha 1 treatment for patients with sepsis1×
- paperThymosin alpha 1 and HIV-1: recent advances and future perspectives1×
- paperEditorial1×
- paperARA 290 for treatment of small fiber neuropathy in sarcoidosis1×
- paperEarly monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression1×
- paperARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception1×
- paperA Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema1×
- paperCibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis1×
- paperImprovement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand1×
- paperA method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS1×
- paperNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions1×
- paperAn immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma1×
- paperOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse1×
- paperThe Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease1×
- paperSmall-Molecule-Directed Hepatocyte-Like Cell Differentiation of Human Pluripotent Stem Cells1×
- paperEvaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents1×
- paperEfficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy1×
- paperHepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure1×
- paperThe development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases1×
- paperThe antioxidant glutathione1×
- paperGlutathione Component of Antioxidant Status in Menopausal Women with Insomnia1×
- paperGlutathione, an Antioxidant Tripeptide: Dual Roles in Carcinogenesis and Chemoprevention1×
- paperGlutathione and peroxisome redox homeostasis1×
- paper[Metabolism and antioxidant function of glutathione]1×
- paperInvolvement of glutathione/glutathione S-transferase antioxidant system in butyrate-inhibited vascular smooth muscle cell proliferation1×
- paperVersatile Nanodrugs Containing Glutathione and Heme Oxygenase 1 Inhibitors Enable Suppression of Antioxidant Defense System in a Two-Pronged Manner for Enhanced1×
- paperUterine non-enzymatic antioxidant defence mechanisms (glutathione, vitamin C, copper and zinc) in diagnosis of canine pyometra1×
- paperIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats1×
- paperThe growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti1×
- paperThe influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus1×
- paperMelanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease1×
- paperOrally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis1×
- paperPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation1×
- paperStructural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue1×
- paperInhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role f1×
- paperDrug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model1×
- paperEffects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide1×
- paperNew insights into the functions of alpha-MSH and related peptides in the immune system1×
- paperNAD(+) metabolism and its roles in cellular processes during ageing1×
- paperNAD⁺ in aging, metabolism, and neurodegeneration1×
- paperThe Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update1×
- paperNAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential1×
- paperNAD(+) homeostasis in health and disease1×
- paperNicotinamide Adenine Dinucleotide (NAD(+))-Dependent Signaling in Neurological Disorders1×
- paperImpaired nicotinamide adenine dinucleotide (NAD(+) ) metabolism in diabetes and diabetic tissues: Implications for nicotinamide-related compound treatment1×
- paperThe kynurenine pathway: a finger in every pie1×
- paperSelank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats1×
- paperEffect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress1×
- paperThe Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress1×
- paperSelank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex i1×
- paperSelank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission1×
- paperGABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells1×
- paperTesamorelin1×
- paperTesamorelin1×
- paperTesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy1×
- paperTesamorelin: a review of its use in the management of HIV-associated lipodystrophy1×
- paperTesamorelin update1×
- paperTesamorelin, a human growth hormone releasing factor analogue1×
- paperNAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial 1×
- paperAdipose tissue as a source of nicotinamide N-methyltransferase and homocysteine1×
- paperReduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice1×
- paperSmall molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells1×
- paperGlucose availability regulates nicotinamide N-methyltransferase expression in adipocytes1×
- paperSelective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice1×
- paperAOD-9604 Metabolic1×
- paperAOD-9604 does not influence the WADA hGH isoform immunoassay1×
- paperHuman sports drug testing by mass spectrometry1×
- paperObesity drugs in clinical development1×
- paperAnalytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls1×
- paperGateways to clinical trials1×
- paperOverview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties1×
- paperEpitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity1×
- paperEpitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro1×
- paperThe Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy1×
- paperCorrection: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity1×
- paperThe Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction1×
- paperMetabolic regulation of kisspeptin - the link between energy balance and reproduction1×
- paperKisspeptin and Glucose Homeostasis1×
- paperKisspeptin in the Prediction of Pregnancy Complications1×
- paperKisspeptin as a Behavioral Hormone1×
- paperKisspeptin as a potential biomarker throughout pregnancy1×
- paperKisspeptin and its Effect on Mammalian Spermatogensis1×
- paperKisspeptin and Testicular Function-Is it Necessary?1×
- paperMOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation1×
- paperMOTS-c Functionally Prevents Metabolic Disorders1×
- paperMOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus1×
- paperMitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination1×
- paperMOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria1×
- paperThe mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus1×
- paperMOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes1×
- paperTirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis1×
- paperTirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial1×
- paperSemaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity1×
- paperEfficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 31×
- paperBody composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight1×
- paperTirzepatide: A Review in Type 2 Diabetes1×
- paperVasoactive intestinal peptide1×
- paperTherapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes1×
- paperVasoactive intestinal peptide in the heart1×
- paperRecent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system1×
- paperVasoactive intestinal peptide. Messenger in a neuroimmune axis1×
- paperVasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery1×
- paperVasoactive intestinal peptide in the lung1×
- paperVasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases1×
- paperEliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression1×
- paperSenolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes1×
- paperThe disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI1×
- paperTargeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline1×
- paperFOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway1×
- paperFOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation1×
- paperFOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells1×
- paperFOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice1×
- paperPralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN1×
- paperDetermination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass1×
- paperThe Safety and Efficacy of Growth Hormone Secretagogues1×
- paperGrowth hormone-releasing peptides1×
- paperGrowth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells1×
- paperGHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans1×
- paperGrowth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation1×
- paperGrowth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms1×
- paperGrowth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency1×
- paperUse of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure1×
- paperGrowth hormone-releasing peptide (GHRP)1×
- paperGrowth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism1×
- paperN-aminoimidazolidin-2-one peptidomimetics1×
- paperOn a peptidomimetic growth hormone-releasing peptide1×
- paperThe cardiovascular action of hexarelin1×
- paperHexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway1×
- paperHexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation1×
- paperImplications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases1×
- paperHexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury1×
- paperGhrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats1×
- paperHexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy1×
- paperHexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice1×
- paperHumanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases1×
- paperRole of humanin, a mitochondrial-derived peptide, in cardiovascular disorders1×
- paperHumanin: A mitochondria-derived peptide with emerging properties1×
- paperMitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases1×
- paperThe emerging role of mitochondrial derived peptide humanin in the testis1×
- paperMitochondrial stress and mitokines in aging1×
- paperAn evidence of Humanin-like peptide and Humanin mediated cryosurvival of spermatozoa in buffalo bulls1×
- paperThe LL-37 domain: A clue to cathelicidin immunomodulatory response?1×
- paperLL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity1×
- paperAntimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications1×
- paperRosacea: Pathogenesis and Therapeutic Correlates1×
- paperUnique features of human cathelicidin LL-371×
- paperThe roles of cathelicidin LL-37 in immune defences and novel clinical applications1×
- paperThe human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections1×
- paperThe human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung1×
- paperElamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice1×
- paperSS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting1×
- paperPotential Therapeutic Candidates for Age-Related Macular Degeneration (AMD)1×
- paperTargeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model1×
- paperElamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential1×
- paperMitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression1×
- paperMitochondrial protein interaction landscape of SS-311×
- paperElamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages1×
- paperEfficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double1×
- paperCagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity1×
- paperDevelopment of Cagrilintide, a Long-Acting Amylin Analogue1×
- paperEfficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis1×
- paperCagrilintide lowers bodyweight through brain amylin receptors 1 and 31×
- paperSermorelin: a better approach to management of adult-onset growth hormone insufficiency?1×
- paperAdvances in the detection of growth hormone releasing hormone synthetic analogs1×
- paperSermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency1×
- paperA potentially effective drug for patients with recurrent glioma: sermorelin1×
- paperIn-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides1×
- paperA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis1×
- paperGlucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial1×
- paperDose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semagluti1×
- paperSurvodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial1×
- paperSurvodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction1×
- paperSurvodutide Once Weekly for the Treatment of Adults with Obesity1×
- paperEfficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis1×
- paperSurvodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)1×
Sources are pulled from the site’s own data — every study record, every compound’s citation list, and every regulatory entry — so this list is the citation count. How the evidence is graded →